RecruitingNot ApplicableNCT03303547

Concordance of Imaging and Pathology Diagnosis of Extranodal Tumour Deposits

Sponsor

Imperial College London

Enrollment

200 participants

Start Date

Oct 16, 2017

Study Type

INTERVENTIONAL

Conditions

Adenocarcinoma of the Rectum

Summary

Any patient with a suspected primary adenocarcinoma of the colon, sigmoid or rectum undergoing surgery are eligible. The date of surgery must be known prior to registration. This trial aims to determine if image mapping techniques can improve the concordance between imaging and pathology detection of tumour deposits. Lymph nodes and tumour deposits will be identified on pre-operative scans and mapped by radiologists then shared with pathologists prior to processing the resected specimen. Patients will be managed at their local hospital with standard follow-up. Patients will be followed up for 5 years.

Eligibility

Min Age: 16 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing what CT scans and MRI show before surgery to what doctors actually find during colon or rectal cancer surgery — specifically looking at small tumour deposits that can spread near the bowel, to improve how doctors use scans to guide treatment decisions. **You may be eligible if...** - You are suspected or confirmed to have adenocarcinoma (a type of cancer) of the colon, sigmoid colon, or rectum - Your cancer can be removed with surgery - You have had imaging to check how far the cancer has spread **You may NOT be eligible if...** - Your cancer is not confirmed as adenocarcinoma after surgery - Your cancer cannot be surgically removed - You are unable to give consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTMRI mapping to guide pathological sampling of extranodal tumour deposits

Radiologist to mark areas where extranodal disease is identified on MRI. The pathologist will use this to take additional samples for analysis. This will allow better pathological staging and will affect treatment decisions for patients.